NYSE:EW - Edwards Lifesciences Stock Price, Forecast & News

Edwards Lifesciences' stock was trading at $197.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EW stock has increased by 0.4% and is now trading at $198.15. View which stocks have been mosted impacted by Coronavirus.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 6 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Edwards Lifesciences.

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Edwards Lifesciences.

Edwards Lifesciences Corp (NYSE:EW) issued its quarterly earnings results on Thursday, January, 30th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.49 by $0.03. The medical research company had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.15 billion. Edwards Lifesciences had a return on equity of 31.73% and a net margin of 24.08%. Edwards Lifesciences's quarterly revenue was up 20.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.17 earnings per share. View Edwards Lifesciences' earnings history.

Edwards Lifesciences's stock split on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were distributed to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided EPS guidance of $6.15-6.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.98. The company issued revenue guidance of $4.6-5.0 billion, compared to the consensus revenue estimate of $4.70 billion.

22 equities research analysts have issued 12 month price objectives for Edwards Lifesciences' stock. Their forecasts range from $175.00 to $300.00. On average, they expect Edwards Lifesciences' stock price to reach $252.05 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price. View analysts' price targets for Edwards Lifesciences.

Media coverage about EW stock has trended very negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Edwards Lifesciences earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutEdwards Lifesciences.

Edwards Lifesciences saw a increase in short interest in March. As of March 13th, there was short interest totaling 2,322,900 shares, an increase of 7.5% from the February 27th total of 2,160,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.1% of the company's stock are sold short. View Edwards Lifesciences' Current Options Chain.

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Insulet (PODD), Steris (STE), Varian Medical Systems (VAR) and Masimo (MASI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Home Depot (HD), Visa (V), Broadcom (AVGO), CVS Health (CVS), Mastercard (MA) and QUALCOMM (QCOM).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (4.28%), FMR LLC (3.88%), Bank of New York Mellon Corp (2.97%), Sands Capital Management LLC (2.91%), Jennison Associates LLC (2.35%) and Capital Research Global Investors (2.24%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View institutional ownership trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Jennison Associates LLC, Nuveen Asset Management LLC, Alliancebernstein L.P., Thrivent Financial for Lutherans, Marshall Wace North America L.P., Bank of New York Mellon Corp, and Bessemer Group Inc.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem, and William J Phd Link. View insider buying and selling activity for Edwards Lifesciences.

EW stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Capital International Investors, FMR LLC, UBS Asset Management Americas Inc., Amundi Pioneer Asset Management Inc., Prudential Financial Inc., William Blair Investment Management LLC, and Captrust Financial Advisors. View insider buying and selling activity for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EW stock can currently be purchased for approximately $198.15.

Edwards Lifesciences has a market capitalization of $41.44 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $5.57 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe. View additional information about Edwards Lifesciences.

The official website for Edwards Lifesciences is http://www.edwards.com/.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]